EP Patent

EP3318277A1 — Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases

Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2018-05-09 · 8y expired

What this patent protects

The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

USPTO Abstract

The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

Drugs covered by this patent

Patent Metadata

Patent number
EP3318277A1
Jurisdiction
EP
Classification
—
Expires
2018-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Centre National de la Recherche Scientifique CNRS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.